Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

IL-17 inhibitors

10 evidence topics · 10 sources

Brodalumab versus ustekinumab and placebo: week 12 outcomes in Trial 2
Outcome at Week 12, Trial 2, n (%)SILIQ 210 mg Q2W (N=612)Ustekinumab (N=300)Placebo (N=309)
PASI 75 response“528 (86)”“210 (70)”“25 (8)”
PASI 100 response“272 (44)”“65 (22)”“2 (1)”
BE RADIANT: bimekizumab versus secukinumab, PASI 100 at weeks 16 and 48 and oral candidiasis

“A total of 1005 patients were screened and 743 were enrolled; 373 patients were assigned to receive bimekizumab and 370 to receive secukinumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At week 16, a total of 230 patients (61.7%) in the bimekizumab group and 181 (48.9%) in the secukinumab group had a 100% reduction from baseline in the PASI score (PASI 100) (adjusted risk difference, 12.7 percentage points; 95% confidence interval [CI], 5.8 to 19.6); bimekizumab was shown to be noninferior and superior to secukinumab (P<0.001 for noninferiority and superiority).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At week 48, a total of 250 patients (67.0%) treated with bimekizumab had a PASI 100 response, as compared with 171 patients (46.2%) treated with secukinumab (adjusted risk difference, 20.9 percentage points; 95% CI, 14.1 to 27.7; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Oral candidiasis occurred more often with bimekizumab (72 patients, 19.3%) than with secukinumab (11 patients, 3.0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“(Funded by UCB Pharma; BE RADIANT ClinicalTrials.gov number, NCT03536884.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Decision aid: IL-17 inhibitors
AgentRoughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months?What is the likelihood of staying on this treatment for more than 1 year?
Bimekizumab“54%”“Not known at present”
Brodalumab“50%”“Not known at present”
Ixekizumab“53%”“77–83% chance”
Secukinumab“47%”“80–83% chance”
Network meta-analysis: anti-IL-17 agents compared with placebo and with other classes